Stay updated with breaking news from Concept Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NDA submission for etripamil in patients with PSVT expected in October 2023Data featured during oral session at Heart Rhythm 2023 Annual Meeting support the potential of etripamil in patients with... -Today at 07:37 am- MarketScreener
Astria Therapeutics, Inc. , a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and... | June 5, 2023
- NDA submission for etripamil in patients with PSVT currently on track for 3Q23 - Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on... | May 11, 2023
Astria Therapeutics, Inc. , a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and... | April 28, 2023
/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...